(Q40883177)

24 September 2017

1 reference

title

Immunosuppressive drug therapy in lupus nephritis (English)

1 reference

24 September 2017

Donadio JV Jr

1

1 reference

PubMed ID

8447299

24 September 2017

Glassock RJ

series ordinal

2

1 reference

24 September 2017

1 March 1993

1 reference

American Journal of Kidney Diseases

24 September 2017

1 reference

24 September 2017

21

1 reference

24 September 2017

239-250

1 reference

24 September 2017

3

1 reference

Chemical action and pharmacology of methotrexate, azathioprine and cyclophosphamide in man

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

The Effects of Azathioprine and 6 mp on Immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Immunodepressant activity and 6-mercaptopurine levels after administration of 6-mercaptopurine and azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

STUDIES ON THE MECHANISM OF ACTION OF METHOTREXATE AND CYCLOPHOSPHAMIDE ON CONTACT SENSITIVITY IN THE GUINEA PIG

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Sensitivity of murine B- and T-lymphocytes to oxazaphosphorine and non-oxazaphosphorine nitrogen mustards

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Oxazaphosphorines as biological response modifiers--experimental and clinical perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

The Effect of Treatment with Prednisone and Nitrogen Mustard on the Renal Lesions and Life Span of Patients with Lupus Glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

NIH conference. Lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Azathioprine and Acute Restrictive Lung Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Cyclophosphamide therapy and interstitial pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

The use of cultured rat embryos to evaluate the teratogenic activity of serum: cadmium and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Cytotoxic drugs in pregnancy. Review of reported cases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Renal agenesis after first trimester exposure to chlorambucil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Fetal effects during cyclophosphamide and irradiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Letter: Teratogenic effects of combination chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Treatment of Lupus Nephritis with Prednisone and Combined Prednisone and Azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Bladder Complications in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus or Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Cyclophosphamide-induced bladder toxicity in wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Wegener Granulomatosis: An Analysis of 158 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Intermittent intravenous cyclophosphamide therapy for lupus nephritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

The histological effects of nitrogen mustards on human tumors and tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Alkylating agents and human spermatogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Gonadal function in boys with steroid-responsive nephrotic syndrome treated with cyclophosphamide for short periods

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

The value of the renal biopsy in lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

The treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Azathioprine and prednisone in the treatment of adults with lupus nephritis. Clinical, histological, and immunological changes with therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Effect of Azathioprine on Renal Histology and Function in Lupus Nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Cyclophosphamide in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Cyclophosphamide in Treatment of Systemic Lupus Erythematosus: 7 Years' Experience

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Azathioprine in the treatment of systemic lupus erythematosus. A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Effect of treatment on the evolution of renal abnormalities in lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

The clinical course of the proliferative and membranous forms of lupus nephritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

Cyclophosphamide: to pulse or not to pulse?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980741-4

7 January 2021

10.1016/S0272-6386(12)80741-4

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

8447299